W
WAVEMAN · COMPANY
ALT · Altimmune, Inc.
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

ALT

Altimmune, Inc.
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001326190
CLUSTER · 3 INSIDERSC-SUITE BUYING · 2☆ WATCH
INSIDER NET · 180D
$154.2K
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
3
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
146
13F, latest reported quarter
REVENUE GROWTH
+105.0%
XBRL, annual
NET MARGIN
-
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net +$154.2K over 180 days
+$44.2K over 90 days
more than 78% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
146 funds added or opened last quarter
more than 78% of Pharma & Biotech
REVENUE
+105.0% year over year
more than 86% of Pharma & Biotech
MARGIN
no margin: this company reports no revenue to divide by
BUYBACKS
no share repurchases reported
SHORT
26.7% of shares outstanding short · 11.4 days to cover · settled 2026-07-31
more than 99% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
3 insiders independently bought a net $154.2K — no planned sales are queued against it.
146 funds added or opened positions in the latest 13F quarter, of 211 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -13.9%
-13.9%12M
-31%+1%+33%+65%2025-092025-102025-122026-032026-052026-072026-09 2026-03-06 · Durso Jerome Benedict bought $70.8K2025-12-22 · Durso Jerome Benedict bought $51.6K2025-12-23 · GILL JOHN bought $51.2K2026-04-01 · Durso Jerome Benedict bought $47.1K2026-08-13 · Durso Jerome Benedict bought $44.2K2026-04-01 · WEAVER GREGORY L bought $31.5K2026-04-06 · GILL JOHN bought $31.4K2026-01-08 · Pisano Wayne bought $20.4K2026-03-06 · WEAVER GREGORY L bought $17.7K2026-01-05 · Sohn Catherine A. bought $2.1K2025-12-29 · Jorkasky Diane bought $2.0K
INSIDER BUY
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
3 insiders reported buying shares.
The record shows a net $154.2K bought by insiders over 180 days, 146 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Altimmune, Inc. insiders bought a net $154.2K of stock across 31 Form 4 purchases and sales, with 3 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Durso Jerome Benedict
President and CEO
BUY
2026-08-13
15,000.0
$44.2K
GILL JOHN
Director
BUY
2026-04-06
9,200.0
$31.4K
WEAVER GREGORY L
Chief Financial Officer
BUY
2026-04-01
10,000.0
$31.5K
Durso Jerome Benedict
President and CEO
BUY
2026-04-01
15,000.0
$47.1K
WEAVER GREGORY L
Chief Financial Officer
BUY
2026-03-06
5,000.0
$17.7K
31 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 26 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
20,385,284.0 sh
$62.0M
Deep Track Capital, LP
19,250,000.0 sh
$58.5M
STATE STREET CORP
12,098,540.0 sh
$36.8M
TCG Crossover Management, LLC
10,000,000.0 sh
$30.4M
VANGUARD CAPITAL MANAGEMENT LLC
8,177,752.0 sh
$24.9M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
GMO U.S. Small Cap Value Fund
$190.9K POSITION · AS OF 2026-02-28
0.4%
Invesco NASDAQ Future Gen 200 ETF
$54.3K POSITION · AS OF 2026-02-28
0.4%
Virtus Biotech Clinical Trials Etf
$136.2K POSITION · AS OF 2026-04-30
0.4%
ALPS Medical Breakthroughs ETF
$400.8K POSITION · AS OF 2026-02-28
0.3%
VANGUARD MARKET NEUTRAL FUND
$1.1M POSITION · AS OF 2026-03-31
0.2%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$13.4M POSITION · AS OF 2026-03-31
0.2%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 18 registered trials, 2 still enrolling or running — a status change here is dated weeks before the press release
10
Phase 1
0 ACTIVE
6
Phase 2
1 ACTIVE
1
Phase 3
1 ACTIVE
1
Not applicable
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$8.0M
$1.8M
$2.4M
-78%
—
2024
$6.1M
$2.5M
$2.4M
-21%
—
2023
$5.5M
$2.1M
$2.6M
+23%
—
2022
$2.9M
$7.3M
$1.2M
+80%
—
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$41.0K$20.0K$426.0K$-68.0K
OPERATING INCOME$-94.5M$-103.2M$-95.9M$-87.7M
NET INCOME$-88.1M$-95.1M$-88.4M$-84.7M
EPS (DILUTED)-1.00-1.34-1.66-1.81
OPERATING CASH FLOW$-67.5M$-79.8M$-75.8M$-62.6M
CASH$43.8M$36.9M$135.1M$111.1M
LONG-TERM DEBT$34.3M——$4.6M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →